Acute coronary syndrome in elderly: aspects of patient management

Coronary heart disease is the leading cause of death worldwide. Over the past few decades, life expectancy has increased, which has led to an aging population in developed countries, so the average age of patients with acute coronary syndrome (ACS) has steadily increased in recent decades. The inclusion of elderly and senile patients in randomized clinical trials does not reflect the age-related association of these diseases. However, antithrombotic therapy and interventional treatment are the basis of treatment in patients with ACS of any age, including the elderly. For older patients, there may be a mismatch between chronological and biological age. The question of how close the treatment of elderly patients with ACS is to the level of current recommendations and whether it is possible to apply them unconditionally in this group of patients does not have a definite answer. Current recommendations and the underlying randomized clinical trials are focused on any one disease, whereas in the elderly in most cases multimorbid pathology occurs. In general, elderly patients with ACS should be treated using the same methods as younger patients, however, the presence of comorbid diseases in an elderly patient naturally increases the risk of complications, makes the patient’s prognosis heavier, significantly affects treatment tactics, limits the possibility of using conventional approaches when choosing a drug therapy.

1. Moran A.E., Forouzanfar M.H., Roth G.A. et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the global burden of disease 2010 study. Circulation 2014;129(14): 1483–92. DOI: 10.1161/CIRCULATIONAHA.113.004042.

2. Kontsevaya A.V., Kalinina A.M., Koltunov I.E., Oganov R.G. Socioeconomic damage by acute coronary syndrome in Russian Federation. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology 2011;7(2):158–66. (In Russ.)

3. United Nations. Department of Economic and Social Affairs. Population Division (2015). World Population Ageing 2015 (ST/ESA/SER.A/390).

4. Lee P.Y., Alexander K.P., Hammill B.G. et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001;286(6):708–13. DOI: 10.1001/jama.286.6.708.

5. Lopes R.D., Gharacholou S.M., Holmes D.N. et al. Cumulative incidence of death and rehospitalization among the elderly in the first year after NSTEMI. Am J Med 2015;128(6):582–90. DOI: 10.1016/j.amjmed.2014.12.03.

6. Gilyarov M.Yu., Zheltoukhova M.O., Konstantinova E.V. et al. Features of the treatment of acute coronary syndrome in elderly patients: experience of the City Clinical Hospital No. 1 named after N.I. Pirogov. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology 2017;13(2):164–70. (In Russ.)

7. Manfrini O., Dorobantu M., Vasiljevic Z. et al. Acute coronary syndrome in octogenarian patients: results from the international registry of acute coronary syndromes in transitional countries (ISACS-TC) registry. Eur Heart J Suppl 2014;16(Suppl A);87–94. DOI: 10.1093/eurheartj/sut019.

8. White H.D., Westerhout C.M., Alexander K.P. et al. Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Eur Heart J Acute Cardiovasc Care 2016;5(3):231–42. DOI: 10.1177/2048872615581502.

9. Alexander K.P., Roe M.T., Chen A.Y. et al. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005;46(8):1479–87. DOI: 10.1016/j.jacc.2005.05.084.

10. Suaya J.A., Stason W.B., Ades P.A. et al. Cardiac rehabilitation and survival in older coronary patients. J Am Coll Cardiol 2009;54(1):25–33. DOI: 10.1016/j.jacc.2009.01.078.

11. Sachdev M., Sun J.L., Tsiatis A.A. et al. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J Am Coll Cardiol 2004;43(4):576–82. DOI:10.1016/j.jacc.2003.10.031.

12. WHO (2017). Dementia. Available at: http://www.who.int/news-room/factsheets/detail/dementia.

13. WHO(2017). Mental health of older adults. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/mentalhealth-of-older-adults.

14. Jokhadar M., Wenger N.K. Review of the treatment of acute coronary syndrome in elderly patients. Clin Interv Aging 2009;4:435–44. DOI: 10.2147/CIA.S3035.

15. Pazan F., Weiss C., Wehling M. The FORTA (Fit fOR The Aged) List 2018: Third Version of a Validated Clinical Tool for Improved Drug Treatment in Older People. Drugs Aging 2019;36(5):481–4. DOI. 10.1007/s40266-019-00669-6.

16. Husted S., James S., Becker R.C. et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 2012;5(5):680–8. DOI: 10.1161/CIRCOUTCOMES.111.964395.

17. Wiviott S.D., Braunwald E., McCabe C.H. et al. Prasugrel versus сlopidogrel in рatients with аcute сoronary syndromes. N Engl J Med 2007;357(20):2001–15. DOI: 10.1056/NEJMoa0706482.

18. Connolly S., Pogue J., Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367(9526):1903–12. DOI: 10.1016/S0140-6736(06)68845-4.

19. Lopes R.D., Rao M., Simon D.N. et al. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Am J Med 2016;129(6):592–9. DOI: 10.1016/j.amjmed.2015.12.026.

20. Capodanno D., Angiolillo D.J. Antithrombotic therapy in the elderly. J Am Coll Cardiol 2010;56(21):1683–92. DOI: 10.1016/j.jacc.2010.04.063.

21. Valgimigli M., Bueno H., Byrne R.A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39(3):213–60. DOI: 10.1093/eurheartj/ehx419.

22. Antman E.M., Morrow D.A., McCabe C.H. et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354(14):1477–88. DOI: 10.1056/NEJMoa060898.

23. Gimbel M.E., Ten Berg J.M. Management of elderly patients with a non-ST-segment-elevation acute coronary syndrome. Neth Heart J 2017;25(7–8):409–15. DOI: 10.1007/s12471-017-1002-3.

24. Yusuf S., Mehta S.R., Chrolavicius S. et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. N Engl J Med 2006;354(14):1464–76. DOI: 10.1056/NEJMoa055443.

25. Catapano A.L., Graham I., de Backer G. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016;37(39):2999–3058. DOI: 10.1093/eurheartj/ehw272.

26. Waters D.D., Guyton J.R., Herrington D.M. et al. Treating to New Targets (TNT) Study: does lowering lowdensity lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004;93(2):154–8. DOI: 10.1016/j.amjcard.2003.09.031.

27. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339(19):1349–57. DOI: 10.1056/NEJM199811053391902.

28. Shepherd J., Blauw G.J., Murphy M.B. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360(9346):1623–30. DOI: 10.1016/S0140-6736(02)11600-X.

29. Minuzzo L., Santos E.S., Timerman A. Association between angiotensinconverting enzyme inhibitors and troponin in acute coronary syndrome. Arq Bras Cardiol 2014;103(6):513–20. DOI: 10.5935/abc.20140155.

30. Soukoulis V., Boden W.E., Smith S.C., O’Gara P.T. Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res 2014;114(12):1944–58. DOI: 10.1161/CIRCRESAHA.114.302804.

31. De Alencar Neto J.N. Morphine, Oxygen, Nitrates, and Mortality Reducing Pharmacological Treatment for Acute Coronary Syndrome: An Evidence-based Review. Cureus 2018;10(1):2114. DOI: 10.7759/cureus.2114.

32. Dai X., Busby-Whitehead J., Alexander K.P. Acute coronary syndrome in the older adults. J Geriatr Cardiol 2016;13(2):101–8. DOI: 10.11909/j.issn.1671-5411.2016.02.012.

33. Armstrong P.W., Gershlick A.H., Goldstein P. et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013; 368(15):1379–87. DOI: 10.1056/NEJMoa1301092.

34. White H.D., Braunwald E., Murphy S.A. et al. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACTTIMI 25. Eur Heart J 2007;28(9):1066–71. DOI: 10.1093/eurheartj/ehm081.

35. Thiemann D.R., Coresh J., Shulman S.P. et al. Lack of Benefit for Intravenous Thrombolysis in Patients With Myocardial Infarction Who Are Older Than 75 Years. Circulation 2000;101(19):2239-46. DOI: 10.1161/01.CIR.101.19.2239.

36. Khan M.G. Thrombolytic therapy. In: Cardiac Drug Therapy. Totowa: Humana Press, 2007.

37. Gale C.P., Cattle B.A., Woolston A. et al. Resolving inequalities in care? Reduced mortality in the elderly after acute coronary syndromes. The Myocardial Ischaemia National Audit Project 2003–2010. Eur Heart J 2012;33(5):630–9. DOI: 10.1093/eurheartj/ehr381.

38. Sauderson C.E., Brogan R.A., Simms A.D. et al. Acute coronary syndrome management in older adults: guidelines, temporal changes and challenges. Age and Ageing 2014;43(4):450–5. DOI: 10.1093/ageing/afu034.

39. Stone G.W., Witzenbichler B., Guagliumi G. et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358(21):2218–30. DOI: 10.1056/NEJMoa0708191.

40. Germing A., Bojara W., Lawo T. et al. Bleeding complications associated with glycoprotein IIβ/IIIα inhibitors in patients 80 years of age and older undergoing percutaneous coronary intervention. Exp Clin Cardiol 2010;15(3):57–60.

41. Sandhya S., Mohanraj P. Clinical presentation, risk factors, complications and outcome of acute myocardial infarction in elderly patients. Int J Res Med Sci 2017;5(11):4765–9. DOI: 10.18203/2320-6012.ijrms20174669.

42. Skolnick A.H., Alexander K.P., Chen A.Y. et al. Characteristics, management, and outcomes of 5,557 patients age > or = 90 years with acute coronary syndromes: results from the CRUSADE Initiative. J Am Coll Cardiol 2007;49(17):1790–7. DOI: 10.1016/j.jacc.2007.01.066.